Navigation Links
Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Date:10/17/2010

ime high, having increased 111 percent over a five-year period.(5)  

About NKTR-181 NKTR-181 is a novel mu-opioid analgesic investigational drug candidate created using Nektar's small molecule polymer conjugate technology.  In preclinical studies, NKTR-181 exhibits a reduced rate of entry into the central nervous system (CNS) providing effective pain relief with fewer CNS-related side effects, such as euphoria, sedation and respiratory depression.  The unique molecular design of the polymer conjugate also prevents conversion of NKTR-181 into free opioids or an abusable form of an opioid.  As a result, NKTR-181 has the potential to be a highly effective analgesic with a favorable safety profile and reduced potential for abuse, misuse and diversion.  

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas.  In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 development program to treat opioid-induced constipation and its NKTR-119 development program for the treatment of pain without constipation side effects.  The company has additional pain compounds in preclinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , September 23, 2014 ... related disorders and increasing number of foreign and domestic ... probiotic in India   ... of the most high growth potential markets worldwide due ... consumers especially among the youth, changing food consumption patterns, ...
Breaking Medicine Technology:EnzymeBioSystems Announces Progress with an Enzyme Compound 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3
... LAKE, N.J., Nov. 9 Par Pharmaceutical Companies, Inc. ... extended the expiration date and increased the purchase price ... in which Par is offering to purchase, for cash, ... approximately 82.7%, of its outstanding 2.875% Senior Subordinated Convertible ...
... , NEW YORK, Nov. 9 MISSION Skincare®, the ... soccer professional Mia Hamm, and other world class athletes, ... beauty aisle of more than 5,000 CVS/pharmacy locations across ... face, body and sun care products, MISSION and CVS/pharmacy ...
Cached Medicine Technology:Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 2Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 3
(Date:9/23/2014)... A new analysis of published studies found that ... cancer versus benign disease in regions where infections ... of lung lesions suspicious for cancer could lead ... additional potential complications and mortality. , Histoplasmosis ... that are often concentrated in bird droppings and ...
(Date:9/23/2014)... California, Davis, and Academia Sinica, the preeminent academic ... entered into a collaborative agreement to develop a ... cutting-edge research with opportunities to translate innovative technologies ... The agreement was signed Sept.12 in Taipei by ... Davis and President Chi-Huey Wong of Academia Sinica. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows ... how it can be treated. , A medically retired ... 2006. His platoon sustained multiple attacks resulting in five ... with combat-related PTSD and honorably discharged from the Army. ... had distanced myself from my friends and family,” recalled ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
Breaking Medicine News(10 mins):Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3
... heart expert calls it ,second-line, medication , , FRIDAY, ... the highly promoted cholesterol-lowering drug Vytorin continued Friday ... the medication,s effectiveness, but only after final trial ... this month when preliminary results of the so-called ...
... WellPoint, Inc. (NYSE:,WLP) announced today that senior ... Conference on January 30, 2008. The presentation is,expected ... All interested parties are invited to listen ... http://www.wellpoint.com and selecting the "Investor,Info" link. Following ...
... Ronit Calderon-Margalit, MD, MPH, Marianna Mazar, MD and Zvi ... Jewish and Arab diabetes sufferers who were admitted to ... whether differences existed between the two groups and, if ... health insurance coverage. The researchers found significant differences. As ...
... Jan. 25 Pizza, nachos, dip and wings ... also have one thing in common:,they can all ... counter heartburn medicine based on dollar sales, is ... tasty heartburn-friendly,alternatives., , Listen to this report ...
... Belgium have significantly advanced the discovery of a pancreatic ... beta cells. If the finding made in mice holds ... obvious target for therapeutic regeneration of beta cells in ... of the research journal Cell, a publication of Cell ...
... The North Carolina,Association of Educators (NCAE) will launch a ... at increasing awareness about good eating,habits and physical fitness ... from NCAE," is slated to run in,newspapers across North ... NCAE logo -- star in an ad campaign to,encourage ...
Cached Medicine News:Health News:FDA Will Wait for Trial Results on Vytorin 2Health News:FDA Will Wait for Trial Results on Vytorin 3Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Elusive pancreatic progenitor cells found in mice 2Health News:NCAE Encourages Minority Youth and Their Families to 'Go-for' Health and Fitness 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: